Literature DB >> 15319274

Focal cortical dysplasias: surgical outcome in 67 patients in relation to histological subtypes and dual pathology.

Susanne Fauser1, Andreas Schulze-Bonhage, Juergen Honegger, Hans Carmona, Hans-Juergen Huppertz, Georgios Pantazis, Sabine Rona, Thomas Bast, Karl Strobl, Bernhard J Steinhoff, Rudolf Korinthenberg, Dietz Rating, Benedikt Volk, Josef Zentner.   

Abstract

The purpose of this study was to assess whether the histological subtype of focal cortical dysplasia and dual pathology affect surgical outcome in patients with medically intractable epilepsy due to focal cortical dysplasia (FCD). We retrospectively analysed the outcome of 67 patients from 2 to 66 years of age at follow-up periods of 6 to 48 months after epilepsy surgery. Histological subtypes were classified according to Palmini and included a few cases with mild histological abnormalities corresponding to the definition of mild malformations of cortical development. The seizure outcome was classified according to Engel and evaluated at the last follow-up visit as well as at follow-up periods of 12 and 24 months after surgery. The outcome in patients with FCD and additional hippocampal pathology (dual pathology) was analysed separately. Distribution of histological subtypes differed in temporal and extratemporal localization, with a significantly higher extratemporal prevalence of FCD type 2. There was a tendency towards better postsurgical outcome related to the last follow-up visit in patients with more subtle abnormalities classified as mild malformations of cortical development (mMCD) (63% Engel Ia), FCD type 1a (67% Engel Ia) and FCD type 1b (55% Engel Ia) compared with patients with FCD type 2a (43% Engel Ia) and FCD type 2b (Taylor type) (50% Engel Ia). Considering the outcome at follow-up periods over 12 and 24 months, complete seizure-freedom was achieved significantly more often in patients with FCD type 1 and mMCD than with FCD type 2, and seizure reduction by less than 75% (Engel IV) occurred in more patients with FCD type 2a compared with the other subgroups. This tendency was seen in the whole patient group and in the extratemporal subgroup. Patients with dual pathology almost always had temporal lobe epilepsy; the outcome in this patient group was generally favourable (66% complete seizure-freedom at the last follow-up visit). The outcome remained almost constant with longer periods of follow-up. We conclude that patients with FCD type 1 and mMCD had a better outcome compared with those with more severe forms of cortical dysplasia. A higher incidence of FCD type 1 in temporal localization did not allow the effects of histological subtype and localization to be separated. A subanalysis of extratemporal FCDs, however, revealed a similar tendency for a better outcome with FCD type 1, suggesting that the histological subtype itself seems to be at least a relevant cofactor influencing postsurgical outcome.

Entities:  

Mesh:

Year:  2004        PMID: 15319274     DOI: 10.1093/brain/awh277

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  38 in total

1.  Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.

Authors:  Jae Seok Lim; Ramu Gopalappa; Se Hoon Kim; Suresh Ramakrishna; Minji Lee; Woo-Il Kim; Junho Kim; Sang Min Park; Junehawk Lee; Jung-Hwa Oh; Heung Dong Kim; Chang-Hwan Park; Joon Soo Lee; Sangwoo Kim; Dong Seok Kim; Jung Min Han; Hoon-Chul Kang; Hyongbum Henry Kim; Jeong Ho Lee
Journal:  Am J Hum Genet       Date:  2017-02-16       Impact factor: 11.025

Review 2.  Post-processing of structural MRI for individualized diagnostics.

Authors:  Pascal Martin; Benjamin Bender; Niels K Focke
Journal:  Quant Imaging Med Surg       Date:  2015-04

3.  Clinical and histopathologic correlates of 11C-alpha-methyl-L-tryptophan (AMT) PET abnormalities in children with intractable epilepsy.

Authors:  Harry T Chugani; Ajay Kumar; William Kupsky; Eishi Asano; Sandeep Sood; Csaba Juhász
Journal:  Epilepsia       Date:  2011-05-13       Impact factor: 5.864

4.  A longitudinal study of surgical outcome of pharmacoresistant epilepsy caused by focal cortical dysplasia.

Authors:  Bo Jin; Jing Wang; Jian Zhou; Shuang Wang; Yuguang Guan; Shuhua Chen
Journal:  J Neurol       Date:  2016-09-08       Impact factor: 4.849

Review 5.  The preoperative evaluation and surgical treatment of epilepsy.

Authors:  Andreas Schulze-Bonhage; Josef Zentner
Journal:  Dtsch Arztebl Int       Date:  2014-05-02       Impact factor: 5.594

Review 6.  Basic mechanisms of epileptogenesis in pediatric cortical dysplasia.

Authors:  Sara Abdijadid; Gary W Mathern; Michael S Levine; Carlos Cepeda
Journal:  CNS Neurosci Ther       Date:  2014-11-18       Impact factor: 5.243

7.  18F-FDG PET in drug-resistant epilepsy due to focal cortical dysplasia type 2: additional value of electroclinical data and coregistration with MRI.

Authors:  Serge Desarnaud; Charles Mellerio; Franck Semah; Agathe Laurent; Elisabeth Landre; Bertrand Devaux; Catherine Chiron; Vincent Lebon; Francine Chassoux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-29       Impact factor: 9.236

8.  Voxel-based morphometric MRI post-processing in MRI-negative focal cortical dysplasia followed by simultaneously recorded MEG and stereo-EEG.

Authors:  Z I Wang; S E Jones; A J Ristic; C Wong; Y Kakisaka; K Jin; F Schneider; J A Gonzalez-Martinez; J C Mosher; D Nair; R C Burgess; I M Najm; A V Alexopoulos
Journal:  Epilepsy Res       Date:  2012-03-04       Impact factor: 3.045

Review 9.  Surgical pathology of epilepsy-associated non-neoplastic cerebral lesions: a brief introduction with special reference to hippocampal sclerosis and focal cortical dysplasia.

Authors:  Hajime Miyata; Tomokatsu Hori; Harry V Vinters
Journal:  Neuropathology       Date:  2013-03-27       Impact factor: 1.906

10.  Focal cortical dysplasia: long term seizure outcome after surgical treatment.

Authors:  T Kral; M von Lehe; M Podlogar; H Clusmann; P Süssmann; M Kurthen; A Becker; H Urbach; J Schramm
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.